Delving into the Latest Updates on SHR-1654 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Rheumatoid Arthritis

Inactive Indication-

Originator Organization

Guangdong Hengrui Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.Guangdong Hengrui Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

评价健康受试者单次皮下注射给予SHR-1654后的安全性和耐受性；评价健康受试者单次皮下注射给予SHR-1654后的药代动力学特征、免疫原性特征、药效学特征；探索健康受试者单次皮下注射给予SHR-1654后的代谢特征；评估单次皮下注射SHR-1654对健康受试者QT/QTc间期的影响。

[Translation]

To evaluate the safety and tolerability of SHR-1654 after a single subcutaneous injection in healthy subjects; To evaluate the pharmacokinetic, immunogenic and pharmacodynamic characteristics of SHR-1654 after a single subcutaneous injection in healthy subjects; To explore the metabolic characteristics of SHR-1654 after a single subcutaneous injection in healthy subjects; To evaluate the effect of a single subcutaneous injection of SHR-1654 on the QT/QTc interval in healthy subjects.

Start Date26 Jan 2024

Sponsor / Collaborator

Guangdong Hengrui Pharmaceutical Co., Ltd.

100 Clinical Results associated with SHR-1654

Login to view more data

100 Translational Medicine associated with SHR-1654

Login to view more data

100 Patents (Medical) associated with SHR-1654

Login to view more data

100 Deals associated with SHR-1654

Login to view more data